ATE470672T1 - Verwendung von cupredoxin-proteine für krebstherapie - Google Patents

Verwendung von cupredoxin-proteine für krebstherapie

Info

Publication number
ATE470672T1
ATE470672T1 AT04780764T AT04780764T ATE470672T1 AT E470672 T1 ATE470672 T1 AT E470672T1 AT 04780764 T AT04780764 T AT 04780764T AT 04780764 T AT04780764 T AT 04780764T AT E470672 T1 ATE470672 T1 AT E470672T1
Authority
AT
Austria
Prior art keywords
cancer therapy
cupredoxin
proteins
cupredoxin proteins
cancer
Prior art date
Application number
AT04780764T
Other languages
English (en)
Inventor
Amanda Chakrabarty
Gupta Tapas Das
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE470672T1 publication Critical patent/ATE470672T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/80Cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41Porphyrin- or corrin-ring-containing peptides
    • A61K38/415Cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04780764T 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie ATE470672T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
ATE470672T1 true ATE470672T1 (de) 2010-06-15

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04780764T ATE470672T1 (de) 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie

Country Status (19)

Country Link
US (4) US7491394B2 (de)
EP (2) EP2263682A1 (de)
JP (1) JP2007502818A (de)
KR (1) KR20060098358A (de)
AP (1) AP2006003537A0 (de)
AT (1) ATE470672T1 (de)
AU (1) AU2004266632A1 (de)
BR (1) BRPI0413574A (de)
CA (1) CA2535581A1 (de)
DE (1) DE602004027637D1 (de)
EA (1) EA009897B1 (de)
EC (1) ECSP066422A (de)
GE (1) GEP20105022B (de)
IL (1) IL173576A0 (de)
NO (1) NO20061168L (de)
NZ (1) NZ545355A (de)
OA (1) OA13308A (de)
TN (1) TNSN06059A1 (de)
WO (1) WO2005018662A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
EP1883650A4 (de) * 2005-05-20 2009-06-10 Univ Illinois Zusammensetzungen und verfahren zur behandlung von hiv-infektionen mit cupredoxin und cytochrom c
AU2006277009A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP1882039A4 (de) * 2005-05-20 2008-08-20 Univ Illinois Zusammensetzungen und verfahren zur behandlung von malaria mit cupredoxin und cytochrom
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
CA2615617A1 (en) * 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
JP2010502765A (ja) * 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
EP2061498A4 (de) * 2006-09-14 2009-11-04 Univ Illinois Zusammensetzungen und verfahren zur krebsvorbeugung mit cupredoxinen
JP2010511408A (ja) * 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をCpGリッチDNAおよびキュプレドキシンで治療するための組成物および方法
EP2117573A4 (de) * 2007-01-11 2011-02-16 Univ Illinois Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen und mutanten davon
JP2010518123A (ja) * 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
MY160424A (en) * 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
WO2016176573A1 (en) * 2015-04-30 2016-11-03 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
JP4881536B2 (ja) 2001-02-15 2012-02-22 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 細胞死を調節する細胞障害性因子
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
EP1883650A4 (de) 2005-05-20 2009-06-10 Univ Illinois Zusammensetzungen und verfahren zur behandlung von hiv-infektionen mit cupredoxin und cytochrom c
EP1882039A4 (de) 2005-05-20 2008-08-20 Univ Illinois Zusammensetzungen und verfahren zur behandlung von malaria mit cupredoxin und cytochrom
CA2615617A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Also Published As

Publication number Publication date
EP2263682A1 (de) 2010-12-22
TNSN06059A1 (en) 2007-10-03
US20060292136A1 (en) 2006-12-28
IL173576A0 (en) 2006-07-05
DE602004027637D1 (de) 2010-07-22
EA009897B1 (ru) 2008-04-28
US20080182782A1 (en) 2008-07-31
EP1653990A1 (de) 2006-05-10
US7888468B2 (en) 2011-02-15
AU2004266632A1 (en) 2005-03-03
WO2005018662A1 (en) 2005-03-03
OA13308A (en) 2007-04-13
US20140179617A1 (en) 2014-06-26
US20060040269A1 (en) 2006-02-23
GEP20105022B (en) 2010-06-25
KR20060098358A (ko) 2006-09-18
US7491394B2 (en) 2009-02-17
EA200600424A1 (ru) 2006-08-25
JP2007502818A (ja) 2007-02-15
US10421801B2 (en) 2019-09-24
CA2535581A1 (en) 2005-03-03
ECSP066422A (es) 2006-11-24
BRPI0413574A (pt) 2006-10-17
EP1653990B1 (de) 2010-06-09
NZ545355A (en) 2009-10-30
NO20061168L (no) 2006-05-15
AP2006003537A0 (en) 2006-04-30

Similar Documents

Publication Publication Date Title
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DE60315135D1 (de) Therapiesonde
EP1597276A4 (de) Therapeutische moleküle
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
EE05505B1 (et) Personaalne teraapiasektsioon
DE60326874D1 (de) Neue verwendung von erythropoietin in herzerkrankungen
DK1755671T3 (da) Terapi af platinresistent cancer
DE60321130D1 (de) Variation von parametern zur neurostimulation
EP1664752A4 (de) Patientenpositionierungssystem für strahlentherapiesystem
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATA19522003A (de) Gag-bindungsproteine
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IS8397A (is) Meðferðarfræðilegar bindisameindir
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
PL1741318T3 (pl) Wykorzystanie elektrod lampy jako anteny
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
DE50311406D1 (de) Verwendung von Formkörpern
EP1682572A4 (de) Proteinexpression
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
ATE455770T1 (de) N-alkynyl-2-heteroaryloxyalkylamide zur verwendung als fungizide
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties